Lerner-Geva Liat, Hirsh-Yechezkel Galit, Novikov Ilia, Farkash Hagit, Boyko Valentina, Spirer Zvi, Passwell Justen H
Women and Children's Health Research Unit, The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel Hashomer, Israel.
Hum Vaccin. 2009 Mar;5(3):136-40. doi: 10.4161/hv.5.3.6811. Epub 2009 Mar 18.
The purpose of this study is to report on the impact of introduction of the varicella vaccine "Varilix" on hospitalizations due to varicella, following licensure in Israel in June, 2000. Data on children hospitalized throughout Israel with the diagnosis of varicella were collected from 1998 until 2003. The national rate of varicella-related hospitalizations decreased during the period 2001-2002. However in 2003 an increase in hospitalization occurred. Based on an assumption that at least 22,000 vaccinations per year were administered, we estimate that there is a greater than 60% reduction in the risk for hospitalization in the immunized population (RR = 0.32; 0.10-1.00). In summary, no national trend in reduction of hospitalization has yet been observed, but a significant reduction in hospitalization is apparent for vaccinated children.
本研究旨在报告2000年6月以色列批准水痘疫苗“Varilix”上市后，其对水痘住院病例的影响。收集了1998年至2003年期间以色列全国范围内诊断为水痘的住院儿童数据。2001 - 2002年期间，全国水痘相关住院率有所下降。然而，2003年住院病例有所增加。基于每年至少接种22,000剂疫苗的假设，我们估计免疫人群住院风险降低超过60%（相对危险度RR = 0.32；0.10 - 1.00）。总之，尚未观察到全国范围内住院率下降的趋势，但接种疫苗的儿童住院率明显降低。
